含有tenoxicam的基于niosomes的配方:一种针对类风湿性疾病的较新的解决方案
Rahul Maheshwari1, Mayank Sharma2, Vijay R Chidrawar1
1School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Green Industrial Park, TSIIC, Jadcherla-509301, Hyderabad, India.
Annales pharmaceutiques francaises
|November 3, 2023
概括
封装西卡姆 (TN) 的非离子表面活性剂体囊泡显示出治疗类风湿性疾病的前景. 优化透皮凝配方 (TN34) 在体外表现出持续的药物释放和显著的抗炎作用.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性疾病需要有效的抗炎治疗.
- 阴体囊泡提供了一个潜在的药物输送系统,可以改善治疗结果.
- 毒 (TN) 是一种抗风湿药物,具有改善分娩的潜力.
研究的目的:
- 开发和评估基于非离子表面活性剂的体囊泡,封装西卡姆 (TN),用于治疗类风湿性疾病.
- 为了配制一个优化的尼奥索姆凝,用于通过皮肤输送.
- 评估尼奥索姆配方的体外抗炎活性和稳定性.
主要方法:
- 使用机械分散制备了尼奥索姆配方,表面活性剂 (span-60),脂质和脱氧化酸盐的比例各不相同.
- 评估了LPS激活的THP-1细胞中的物理化学特性,体外释放和TNF-α抑制.
- 优化的配方 (TN3) 被纳入卡博波尔934凝 (TN34) 中,并在不同的温度下进行稳定性测试.
主要成果:
- 优化的阴带体配方 (TN3) 显示了小囊泡大小 (165±14nm) 和高封装效率 (79.64±1.5%).
- 体凝 (TN34) 呈现出适合的pH值 (6.7),粘度 (6810±3.34 cps) 和扩散性 (19.11±1.87 gm.cm/sec).
- 观察到持续的药物释放 (98.16±0.07%在24小时内) 和显著的抗炎活性 (约75%的TNF-α抑制在48小时内). 冰箱温度 (4±2°C) 被认为是最适合储存的.
结论:
- 西卡姆的通过皮肤的阴osomal配方显示出治疗类风湿性疾病的巨大潜力.
- 开发的尼奥索姆凝提供持续释放和有效的抗炎作用.
- 需要进一步的体内研究来证实治疗疗效.
相关概念视频
Drug Distribution: Tissue Binding
2.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.7K
Drug Dosage Regimen: Overview
3.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.6K
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
456
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
456


